Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 216

1.

EBV/LMP-specific T cells maintain remissions of T and B cell EBV lymphomas after allogeneic bone marrow transplantation.

McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM.

Blood. 2018 Sep 27. pii: blood-2018-07-863654. doi: 10.1182/blood-2018-07-863654. [Epub ahead of print]

PMID:
30262660
2.

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM.

Mol Ther. 2018 Oct 3;26(10):2496-2506. doi: 10.1016/j.ymthe.2018.08.015. Epub 2018 Sep 21.

PMID:
30249388
3.

Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma.

Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):592-603. doi: 10.1200/EDBK_200549. Review.

4.

β2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans.

Graff RM, Kunz HE, Agha NH, Baker FL, Laughlin M, Bigley AB, Markofski MM, LaVoy EC, Katsanis E, Bond RA, Bollard CM, Simpson RJ.

Brain Behav Immun. 2018 Aug 30. pii: S0889-1591(18)30525-7. doi: 10.1016/j.bbi.2018.08.017. [Epub ahead of print]

PMID:
30172948
5.

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.

Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network.

Nat Rev Clin Oncol. 2018 Aug 6. doi: 10.1038/s41571-018-0075-2. [Epub ahead of print] Review.

PMID:
30082906
6.

Cellular immunotherapy for non-Hodgkin lymphoma.

Bollard C.

Clin Adv Hematol Oncol. 2018 Jun;16(6):420-422. No abstract available.

PMID:
30067612
7.

A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae.

Castillo P, Wright KE, Kontoyiannis DP, Walsh T, Patel S, Chorvinsky E, Bose S, Hazrat Y, Omer B, Albert N, Leen AM, Rooney CM, Bollard CM, Cruz CRY.

Mol Ther Methods Clin Dev. 2018 Mar 14;9:305-312. doi: 10.1016/j.omtm.2018.03.003. eCollection 2018 Jun 15.

8.

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.

Allen CE, Marsh R, Dawson P, Bollard CM, Shenoy S, Roehrs P, Hanna R, Burroughs L, Kean L, Talano JA, Schultz KR, Pai SY, Baker KS, Andolina JR, Stenger EO, Connelly J, Ramirez A, Bryant C, Eapen M, Pulsipher MA.

Blood. 2018 Sep 27;132(13):1438-1451. doi: 10.1182/blood-2018-01-828277. Epub 2018 Jul 11.

PMID:
29997222
9.

Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency.

Miller HK, Hanley PJ, Lang H, Lazarski CA, Chorvinsky EA, McCormack S, Roesch L, Albihani S, Dean M, Hoq F, Adams RH, Bollard CM, Keller MD.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1944-1946. doi: 10.1016/j.bbmt.2018.04.030. Epub 2018 May 9.

PMID:
29753156
10.

Introduction to a review series on emerging immunotherapies for hematologic diseases.

Paczesny S, Pavletic SZ, Bollard CM.

Blood. 2018 Jun 14;131(24):2617-2620. doi: 10.1182/blood-2018-04-840793. Epub 2018 May 4. Review.

11.

HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Patel S, Chorvinsky E, Albihani S, Cruz CR, Jones RB, Shpall EJ, Margolis DM, Ambinder RF, Bollard CM.

Mol Ther. 2018 Jun 6;26(6):1435-1446. doi: 10.1016/j.ymthe.2018.04.009. Epub 2018 Apr 12.

PMID:
29724686
12.

A single exercise bout augments adenovirus-specific T-cell mobilization and function.

Kunz HE, Spielmann G, Agha NH, O'Connor DP, Bollard CM, Simpson RJ.

Physiol Behav. 2018 Oct 1;194:56-65. doi: 10.1016/j.physbeh.2018.04.035. Epub 2018 Apr 30.

PMID:
29723594
13.

How I treat T-cell chronic active Epstein-Barr virus disease.

Bollard CM, Cohen JI.

Blood. 2018 Jun 28;131(26):2899-2905. doi: 10.1182/blood-2018-03-785931. Epub 2018 Apr 30. Review.

PMID:
29712633
14.

Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.

McLaughlin LP, Bollard CM, Keller MD.

Front Immunol. 2018 Mar 19;9:556. doi: 10.3389/fimmu.2018.00556. eCollection 2018. Review.

15.

Reprint of: Virus-Specific T Cells: Broadening Applicability.

Barrett AJ, Prockop S, Bollard CM.

Biol Blood Marrow Transplant. 2018 Mar;24(3S):S1-S6. doi: 10.1016/j.bbmt.2017.12.787. Review.

PMID:
29425515
16.

Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.

Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Cruz CR, Karandish S, Truong R, Macedo AB, Bosque A, Kovacs C, Benko E, Piechocka-Trocha A, Wong H, Jeng E, Nixon DF, Ho YC, Siliciano RF, Walker BD, Jones RB.

J Clin Invest. 2018 Feb 1;128(2):876-889. doi: 10.1172/JCI97555. Epub 2018 Jan 22.

17.

Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients.

McCormack SE, Cruz CRY, Wright KE, Powell AB, Lang H, Trimble C, Keller MD, Fuchs E, Bollard CM.

Cytotherapy. 2018 Mar;20(3):385-393. doi: 10.1016/j.jcyt.2017.11.010. Epub 2018 Jan 10.

PMID:
29331266
18.

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.

Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM.

J Clin Oncol. 2018 Apr 10;36(11):1128-1139. doi: 10.1200/JCO.2017.74.3179. Epub 2018 Jan 9.

PMID:
29315015
19.

Developing T-cell therapies for lymphoma without receptor engineering.

Grant M, Bollard CM.

Blood Adv. 2017 Dec 8;1(26):2579-2590. doi: 10.1182/bloodadvances.2017009886. eCollection 2017 Dec 12. Review.

20.

Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study.

Williams KM, Holter-Chakrabarty J, Lindenberg L, Duong Q, Vesely SK, Nguyen CT, Havlicek JP, Kurdziel K, Gea-Banacloche J, Lin FI, Avila DN, Selby G, Kanakry CG, Li S, Scordino T, Adler S, Bollard CM, Choyke P, Gress RE.

Lancet Haematol. 2018 Jan;5(1):e44-e52. doi: 10.1016/S2352-3026(17)30215-6. Epub 2017 Dec 14.

PMID:
29248669

Supplemental Content

Loading ...
Support Center